Abstract
More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antibodies, Neutralizing / immunology*
-
Antibodies, Neutralizing / therapeutic use*
-
COVID-19 / immunology*
-
COVID-19 / virology
-
COVID-19 Drug Treatment*
-
Humans
-
Pandemics / prevention & control
-
SARS-CoV-2 / immunology
-
Serum / immunology